Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Bimatoprost 1 · 1 trial · 3 indications
TAHC was measured using digital imaging analysis and was reported in terminal hairs/centimeters squared (cm\^2). A positive change from Baseline indicated improvement (increase in the number of terminal hairs) and a negative change from Baseline indicated worsening (decrease in the number of terminal hairs).
The SSA score measured scalp hair growth. Using a 7-point scale, participants answered the Question: "Since the start of the study, the amount of my hair has?": Greatly Increased, Moderately Increased, Slightly Increased, Remained the Same, Slightly Decreased, Moderately Decreased or Greatly Decreased. The percentage of participants in each response category is presented.
| Arm | Type | Description |
|---|---|---|
| Stage 1: Bimatoprost Solution 1 Twice Daily | EXPERIMENTAL | Stage 1: Bimatoprost Solution 1 applied evenly onto pre-specified area on the scalp twice daily for 28 days. |
| Stage 1: Bimatoprost Solution 1 Once Daily | EXPERIMENTAL | Stage 1: Bimatoprost Solution 1 applied evenly onto pre-specified area on the scalp once daily for 28 days. |
| Stage 1: Bimatoprost Solution 2 Twice Daily | EXPERIMENTAL | Stage 1: Bimatoprost Solution 2 applied evenly onto pre-specified area on the scalp twice daily for 28 days. |
| Stage 1: Bimatoprost Solution 2 Once Daily | EXPERIMENTAL | Stage 1: Bimatoprost Solution 2 applied evenly onto pre-specified area on the scalp once daily for 28 days. |
| Stage 2: Bimatoprost Solution 1 Twice Daily | EXPERIMENTAL | Stage 2: Bimatoprost Solution 1 applied evenly onto pre-specified area on the scalp twice daily for 6 months. |
| Stage 2: Bimatoprost Solution 2 Twice Daily | EXPERIMENTAL | Stage 2: Bimatoprost Solution 2 applied evenly onto pre-specified area on the scalp twice daily for 6 months. |
| Stage 2: Bimatoprost Vehicle Twice Daily | PLACEBO_COMPARATOR | Stage 2: Bimatoprost Vehicle applied evenly onto pre-specified area on the scalp twice daily for 6 months. |
| Name | Type | Description |
|---|---|---|
| Bimatoprost Solution 1 | DRUG | Bimatoprost Solution 1 applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months. |
| Bimatoprost Solution 2 | DRUG | Bimatoprost Solution 2 applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months. |
| Bimatoprost Vehicle | DRUG | Bimatoprost Vehicle (placebo) applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months. |
Inclusion Criteria: * Mild to moderate male pattern baldness (androgenic alopecia) with ongoing hair loss for at least 1 year * Willingness to maintain same hair style, length and hair color during study * Willingness to have micro-dot-tattoo applied to scalp (Stage 2 only) Exclusion Criteria: * ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Pfizer Inc. | PFE | 6 | PHASE3 | Ritlecitinib higher dose |
| Veradermics, Incorporated | MANE | 4 | PHASE3 | VDPHL01 |
| AbbVie, Inc. | ABBV | 3 | PHASE3 | Upadacitinib |
| Eli Lilly and Company | LLY | 2 | PHASE3 | Baricitinib |
| ICON Plc | ICLR | 1 | PHASE3 | Clascoterone 5%, Vehicle |
| Nektar Therapeutics | NKTR | 1 | PHASE2 | Rezpegaldesleukin |
| Sunshine Biopharma Incorporated | SBFM | 1 | PHASE3 | 5% minoxidil foam |
| Q32 Bio Inc | QTTB | 1 | PHASE2 | bempikibart |
| Forte Biosciences Inc. | FBRX | 1 | PHASE1 | FB102 |
| Absci Corporation | ABSI | 1 | PHASE1 | ABS-201 Single Dose, ABS-201 Multiple Doses |
| HCW Biologics, Inc. | HCWB | 1 | PHASE1 | HCW9302, an IL-2 fusion protein |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE2 | Dupilumab |
Bimatoprost is used for glaucoma, open-angle glaucoma, ocular hypertension, eyebrow hypotrichosis, and alopecia. It is a small molecule developed by AbbVie Inc. for ophthalmology and related conditions. In clinical trials, it has been studied for open-angle glaucoma, ocular hypertension, and androgenic alopecia.
Bimatoprost is a prostaglandin analog that lowers intraocular pressure by increasing the outflow of aqueous humor through the uveoscleral pathway. It is used in ophthalmology for conditions like open-angle glaucoma and ocular hypertension. The drug is also studied for effects on hair growth in conditions such as alopecia.
Bimatoprost is developed by AbbVie Inc., a biopharmaceutical company traded on the NYSE under the ticker ABBV. AbbVie conducts clinical trials for the drug across multiple indications, including glaucoma and alopecia.
Bimatoprost is in Phase 3 clinical development. It has completed four trials, including Phase 3 studies for open-angle glaucoma and ocular hypertension. The drug is investigational and not yet approved for these uses, though it is also studied for other conditions.
Bimatoprost has completed four clinical trials, including NCT03850782, NCT03891446, and NCT04285580 for open-angle glaucoma and ocular hypertension, and NCT01904721 for androgenic alopecia. These trials enrolled a total of 2067 participants across multiple countries.
Bimatoprost is the active ingredient in Latisse, a treatment for eyebrow hypotrichosis. It is also used for glaucoma and ocular hypertension. The drug is developed by AbbVie Inc. and is being studied for additional indications like alopecia.